2Burris HA, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997, 15(6):2403-2413.
3Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of report of randomized clinical trials: Is blinding necessary [J].Controlled Clin Trials, 1996, 17:1-12.
4Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase Ⅱ trial [J]. Ann Oncol, 2003, 14(1) :97-104.
5Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective,randomized phase Ⅲ study of the Gruppo Oncologia dell'Italia Meridionale [J]. Cancer, 2002, 94(4):902-910.
6Gansauge F, Ramadani M, Pressmar J, et al. NSC-631570(Ukrain) in the palliative treatment of pancreatic cancer.Results of a phase Ⅱ trial [J]. Langenbecks Arch Surg, 2002,386(8): 570-574.
7Berlin JD, Catalano P, Thomas JP, et al. Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J]. J Clin Oncol,2002, 20(15): 3270-3275.
8Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J]. Br J Cancer, 2002, 87(2): 161-167.
9Van Cutsem E, van de Velde H, Karasek P, et al. Phase ⅢTrial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer [J]. JClin Oncol, 2004, 22(8):1430-1438.
10Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine+oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase Ⅲ [J]. J Clin Oncol, 2004, 22(14suppl): abstr 4008.
